Regulation of the Placental Renin-Angiotensin-Aldosterone System in Early- and Late-Onset Preeclampsia.

Autor: Artemieva KA; Avtsyn Research Institute of Human Morphology, Petrovsky National Research Center of Surgery, Moscow, Russia. artemjeva_ksenia@mail.ru., Nizyaeva NV; Avtsyn Research Institute of Human Morphology, Petrovsky National Research Center of Surgery, Moscow, Russia., Baev OR; Kulakov National Medical Research Center for Obstetrics, Gynecology, and Perinatology, Ministry of Healthcare of Russian Federation, Moscow, Russia., Romanov AY; Kulakov National Medical Research Center for Obstetrics, Gynecology, and Perinatology, Ministry of Healthcare of Russian Federation, Moscow, Russia., Khlestova GV; Kulakov National Medical Research Center for Obstetrics, Gynecology, and Perinatology, Ministry of Healthcare of Russian Federation, Moscow, Russia., Boltovskaya MN; Avtsyn Research Institute of Human Morphology, Petrovsky National Research Center of Surgery, Moscow, Russia., Shchegolev AI; Kulakov National Medical Research Center for Obstetrics, Gynecology, and Perinatology, Ministry of Healthcare of Russian Federation, Moscow, Russia., Kakturskiy LV; Avtsyn Research Institute of Human Morphology, Petrovsky National Research Center of Surgery, Moscow, Russia.
Jazyk: angličtina
Zdroj: Doklady. Biochemistry and biophysics [Dokl Biochem Biophys] 2022 Dec; Vol. 507 (1), pp. 256-263. Date of Electronic Publication: 2022 Dec 29.
DOI: 10.1134/S1607672922060011
Abstrakt: Preeclampsia (PE) is one of the most dangerous complications of pregnancy, characterized by hypertension, proteinuria, and symptoms of multiple organ failure, which are detected de novo after 20 weeks of pregnancy. The renin-angiotensin-aldosterone system (RAAS) is one of the first to recognize pregnancy and is an important regulator of blood pressure. The placenta has its own RAAS, the role of which in the development of PE is not fully understood. In this work, for the first time, we characterized the expression of RAAS components and miRNAs controlling it in the placenta at various times of PE manifestation. The data obtained will allow the development of a new strategy in the future for the search for therapeutic agents for patients suffering from PE and cardiovascular diseases.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje